Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2023; 11(26): 6083-6090
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6083
Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer
Li Zheng, Li-Hong Gan, Ling Yao, Bin Li, Ya-Qin Huang, Fu-Bao Zhang, Meng-Qi Kuang, Nian Fang
Li Zheng, Li-Hong Gan, Ling Yao, Bin Li, Ya-Qin Huang, Meng-Qi Kuang, Nian Fang, Department of Gastroenterology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China
Fu-Bao Zhang, Department of Stomatology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China
Author contributions: These authors contributed equally to this work.
Supported by Jiangxi Province Major Discipline Academic and Technical Leaders Project, No. 812178084229.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of The First Hospital of Nanchang.
Informed consent statement: Participants in this study and their legal guardians provide informed written consent before the recruitment of the study.
Conflict-of-interest statement: All authors declare that there is no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nian Fang, PhD, Doctor, Department of Gastroenterology, The First Hospital of Nanchang, No. 128 Xiangshan North Road, Nanchang 330008, Jiangxi Province, China. zl13870673345@163.com
Received: June 20, 2023
Peer-review started: June 20, 2023
First decision: July 7, 2023
Revised: July 12, 2023
Accepted: August 11, 2023
Article in press: August 11, 2023
Published online: September 16, 2023
Processing time: 80 Days and 2 Hours
Abstract
BACKGROUND

The incidence and mortality rates of gastric cancer in China are the second-highest in the world, and most patients with gastric cancer lose their chance of surgery by the time of their diagnosis.

AIM

To explore the predictive potential of serum basic fibroblast growth factor and interleukin-1β levels for the effect of first-line chemotherapy in patients with advanced gastric cancer.

METHODS

From the gastric cancer patients admitted to our hospital from May 2019 to April 2023, 84 patients were selected and randomly and equally assigned to the experimental or control group. The FLOT group received the FLOT chemotherapy regimen (composed of oxaliplatin + calcium folinate + fluorouracil + paclitaxel), while the SOX group received the SOX chemotherapy regimen (composed of oxaliplatin + tiga capsules). The clinical efficacy, tumor marker levels, adverse reactions, and survival rates of the two groups were compared 7 days after the end of the relevant treatments.

RESULTS

The target effective rate of the FLOT group was 54.76%, which was much higher than that of the SOX group (33.33%; P < 0.05). After treatment, both the groups demonstrated lower levels of cancer antigen (CEA), carbohydrate antigen 199 (CA199), and peptide tissue antigen (TPS). For several patients before treatment (P < 0.05). Third and fourth grades. In terms of adverse reactions, the level of white blood cells in both the groups was lower. Moreover, the incidence of hand-foot skin reactions in these two study groups was lower (P < 0.05), while those of peripheral neuritis, vomiting, diarrhea, and abnormal liver function were significant (P < 0.05). No statistically significant difference was noted between the two groups (P < 0.05). The 1-year survival rate was higher in the FLOT group (P < 0.05).

CONCLUSION

The FLOT regimen was effective in reducing the serum CEA, CA199, and TPS levels as well as in improving the 1-year survival rate of patients with good tolerability, making it worthy of clinical promotion and application.

Keywords: FLOT regimen; SOX regimen; Advanced gastric cancer; First-line chemotherapy; Tissue peptide-specific antigen

Core Tip: The prognosis of HER2-positive gastric cancer patients is generally worse; hence, there is an urgent need to explore new and effective treatments. Gastric cancer is a common malignant tumor disease in the digestive system. Cumulative data suggests that the incidence rate of gastric cancer ranks second among all malignant tumors, and the mortality rate ranks third. Furthermore, there is a rising trend in the incidence rate, which poses a serious threat to the physical and mental health of the population. The rapid development of modern medical technology has promoted the emergence of targeted therapy in clinical practice. However, due to the heterogeneous and complex nature of gastric cancer progression, its application is limited and the progress is slow.